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Abstract 
Background: Whether the use of the radial artery (RA) can improve clinical outcomes in 
coronary artery bypass graft (CABG) surgery remains unclear. The Arterial Revascularization 
Trial (ART) was designed to compare survival after bilateral internal thoracic artery (BITA) 
over single left internal thoracic artery (SITA). In the ART, a large proportion of patients 
(~20%) also received a RA graft instead of a saphenous vein graft (SVG). We aimed to 
investigate the associations between using the RA instead of SVG to supplement SITA or BITA 
grafts and outcomes by performing a post-hoc analysis of the ART. 
Methods: Patients enrolled in the ART (n=3102) were classified based on conduits actually 
received (as treated). The analysis included 2737 patients who received a RA graft (RA group, 
n=632) or SVG only (SVG group, n=2105) in addition to SITA or BITA grafts. The primary 
endpoint was the composite of myocardial infarction, cardiovascular death and repeat 
revascularization at 5 years. Propensity score matching and stratified Cox regression were used 
to compare the two strategies.  
Results: MI, cardiovascular death and repeat revascularization cumulative incidence was 2.3% 
(95%CI 1.1-3.4), 3.5% (95%CI 2.1-5.0) and 4.4% (95%CI 2.8-6.0) in the RA group and 3.4% 
(95%CI 2.0-4.8), 4.0% (95%CI 2.5-5.6) and 7.6% (95%CI 5.5- 9.7) in the SVG group 
respectively. The composite endpoint was significantly lower in the RA group (8.8%; 95%CI 
6.5-11.0) when compared with the SVG group (13.6%; 95%CI 10.8-16.3) (P=0.005). This 
association was present when a RA graft was used to supplement both SITA and BITA grafts 
(interaction P=0.62) 
Conclusions: This post-hoc ART analysis showed that an additional RA was associated with 
lower risk for mid-term major adverse cardiac events when used to supplement SITA or BITA 
grafts.  
 
  
Clinical Perspective  
What is new? 
 The use of a radial artery graft (RA) has been associated with superior angiographic 
patency rates when compared with saphenous vein grafts (SVG), but the clinical impact 
of using the RA remains unclear.  
 We found that the RA used to supplement either single or bilateral internal thoracic 
artery grafts instead of SVG only, was associated with a significantly lower risk for 
major adverse cardiac events with a significantly lower rate of reintervention and 
marginally lower risk for cardiovascular death and subsequent myocardial infarction.  
 
What are the clinical implications? 
 The RA graft is simple to perform as its caliber and handling properties are similar to 
vein grafts, and in view of its superior patency over SVGs, it is an ideal conduit to 
achieve multiple arterial grafting and may improve patient outcomes.  
 
  
Introduction 
Despite increasing interest in additional arterial conduits during coronary artery bypass graft 
(CABG) surgery [1], the search for the optimum additional arterial conduit to supplement the 
left internal thoracic artery continues. The radial artery (RA) has been shown to provide better 
patency rates than saphenous vein grafts (SVG) [2,3] but whether this translates into superior 
clinical outcomes remains unclear. A few randomized controlled trials investigating the effect 
of RA grafts on clinical outcomes were underpowered to detect differences in clinical outcomes 
[4-6]. On the other hand, observational studies that have focused only on survival have reported 
discordant results [7-16].   
The Arterial Revascularization Trial (ART) was designed to compare survival after bilateral 
internal thoracic artery (BITA) versus single left internal thoracic artery (SITA). The interim 
mid-term results (5 years) demonstrated no difference between the groups [1]. A large 
proportion of the ART patients (~20%) received the RA as second conduit to supplement SITA 
graft or as third conduit to supplement BITA grafts, making the ART the largest series of RA 
grafting in the context of a randomized trial involving SITA or BITA.  
We aimed to investigate the associations between the use of a RA graft when used to 
supplement either SITA or BITA grafts and clinical outcomes by performing a post-hoc 
analysis of the ART.  
Methods 
The present study is a post-hoc analysis of 5 year outcomes of the ART trial. This research 
adheres to the principles set forth in the Declaration of Helsinki 
(http://www.wma.net/en/30publications/10policies/b3/index.html). In the ART, the use of the 
RA was based on surgeon’s discretion. For the purpose of the present analysis, patients enrolled 
in the ART (n=3102) were classified based on conduits actually received (as treated principle). 
The present analyses compared the strategy using the RA with or without additional SVG (RA 
group) versus SVG only (SVG group) to supplement single or bilateral internal thoracic artery 
grafts (SITA and BITA).  
The following patients were excluded from the present analyses: neither SVG nor RA used 
(n=328); patients receiving SVG but neither SITA nor BITA graft (n=30); patients receiving a 
RA graft but neither SITA nor BITA used (n=7).  
Trial design 
The ART was approved by the institutional review board of all participating centers, and 
informed consent was obtained from each participant. The protocol for the ART has been 
published [17]. Briefly, the ART is a 2-arm, randomized multicenter trial conducted in 28 
hospitals in 7 countries, with patients being randomized equally to SITA or BITA grafts. 
Eligible patients were those with multivessel coronary artery disease undergoing CABG, 
including urgent patients, with grafting recommended in case of target stenosis ≥75%. Only 
emergency patients (refractory myocardial ischemia/cardiogenic shock) and those requiring 
single grafts or redo CABG were excluded.  
Follow-up  
Questionnaires were sent to study participants by post at 6 months and every year after surgery. 
No clinic visits were planned apart from the routine clinical 6-week post-operative visit. 
Participants were sent stamped addressed envelopes to improve the return rates of postal 
questionnaires. Study co-ordinators contacted participants by telephone to alert them to the 
arrival of the questionnaire and to ask them about medications, adverse events and health 
services resource use. 
Study outcomes  
The primary outcome for this analysis was the composite of major adverse cardiac events 
(MACE) at 5 years including cardiovascular (CV) death, myocardial infarction (MI) and repeat 
revascularization.  The association between the use of a RA graft and MACE individual 
components and overall mortality were also investigated.  
Hospital outcomes analyzed were: hospital mortality, return to the operating room, 
postoperative intra-aortic balloon pump (IABP), renal replacement therapy, sternal wound 
infection, MI, cerebrovascular accident (CVA), repeat revascularization and postoperative 
atrial fibrillation (POAF).  Adverse events were adjudicated by a member(s) of the Clinical 
Event Review Committee blind to the surgical procedure.  
Statistical Analysis 
For baseline characteristics, variables are summarized as mean and SD for continuous variables 
and percentage for categorical variables. Multiple imputation (m=3) was used to address 
missing data. Rubin’s method [18] was used to combine results from each of m imputed data 
sets (Amelia R package).  Due to lack of randomization with regards to receiving RA, a 
propensity score (PS) was generated for each patient from a multivariable logistic regression 
model based on pre-treatment covariables as independent variables with RA versus SVG as a 
binary dependent variable [19]. Covariables included in the PS model were: age, female sex, 
body mass index (BMI), systolic blood pressure (SBP) and diastolic blood pressure (DBP) at 
admission, creatinine, New York Heart Association functional class (NYHA), unstable angina 
(UA), treated hypertension, treated hyperlipidemia, diabetes mellitus (DM), smoking, chronic 
obstructive pulmonary disease (COPD), peripheral vascular disease (PVD), transient ischemic 
attack (TIA), cerebrovascular accident (CVA), myocardial infarction (MI), percutaneous 
coronary intervention (PCI), atrial fibrillation (AF), left ventricular ejection fraction (LVEF), 
dual antiplatelet therapy (DAPT), off-pump surgery, bilateral internal thoracic artery (BITA), 
left main stem disease (LMDS), left anterior descending artery (LAD) disease, circumflex 
artery (CX) disease, diagonal branch (DIA) disease and right coronary artery (RCA) disease. 
Pairs of patients were derived using greedy 1:1 matching with a caliper of width of 0.2 standard 
deviation of the logit of the PS (nonrandom R package). The quality of the match was assessed 
by comparing selected pre-treatment variables in propensity score–matched patients using the 
standardized mean difference (SMD), for which an absolute standardized difference of greater 
than 10% is suggested to represent meaningful covariable imbalance. McNemar's test and 
paired t test were used to assess the statistical significance of the risk difference in short term 
outcomes in the matched sample [19]. A Cox regression model, stratified on the matched pairs 
[19], was used to estimate the associations between treatment and the primary outcome and 
overall mortality. This approach accounts for the within-pair homogeneity by allowing the 
baseline hazard function to vary across matched sets (survival R package). Competing risk 
analysis (prodlim and riskRegression R packages) was used to estimate the associations 
between treatment and the primary endpoint individual components.  As sensitivity analysis, 
the associations between the use of a RA graft and outcomes was tested in a mixed effect Cox 
model to account for clustering effect due to individual surgeons and centers [20] 
(http://CRAN.R-project.org/package=coxme). The association between use of a RA graft and 
outomes was also adjusted for medication at discharge including aspirin, clopidogrel, beta-
blockers, calcium channel antagonists (CCA), statins, and angiotensin converting enzyme 
inhibitors (ACEI) and angiotensin receptors blockers (ARB). Finally, possible modifiers of 
associations tested using interaction analyses were: age < and ≥ 70 years; female vs male sex; 
diabetes vs non diabetes; reduced vs preserved LVEF; SITA vs BITA graft; off- vs on-pump 
surgery.  
All p-values were 2-sided, with p<0.05 were considered to indicate statistical significance. All 
statistical analysis was performed using R Statistical Software (version 3.2.3; R Foundation for 
Statistical Computing, Vienna, Austria). 
Results 
Study sample 
The final population included 2737 patients who received a RA graft (RA group, n=632) or 
SVG only (SVG group, n=2105). Among those who received a RA graft, SITA graft was used 
in 359 patients (57%) and BITA grafts was used in 273 patients (43%). In the RA group, 397 
(63%) patients underwent total arterial revascularization while the remaining 235 (37%) 
received at least 1 additional SVG. In the SVG group, 1330 patients had SITA graft (63%) and 
the remaining 775 (37%) had BITA grafts.  
Grafts configuration and targets details 
Graft configurations and targets characteristics in the RA and SVG groups are summarized in 
Table 1. Overall, the quality (including size and need for endarterectomy) of targets grafted 
using the RA was not superior to targets grafted using SVG in the SVG group. Supplementary 
Table 1 summarizes graft configuration and target details in subjects receiving a RA graft to 
supplement SITA and BITA grafts respectively. When the RA was used to supplement a SITA 
graft, it was preferentially used to graft the circumflex artery (65%) followed by the right 
coronary artery (22%). When the RA was used to supplement BITA grafts, it was preferentially 
used to graft the right coronary artery (64%) followed by the circumflex artery (25%). 
RA usage variation across surgeons and centrers 
The present post-hoc analysis included a total of 157 participating surgeons and 28 cardiac 
centrers. The use of the RA over SVG only significantly varied across surgeons 
(Supplementary Figure 1, information not available in 120 cases marked as #1) and across 
different centers (Supplementary Figure 2).  
Propensity Score matching 
Before matching, the RA and SVG groups showed significant differences in terms of 
preoperative nitrates administration, age, functional NYHA class, rate of BITA grafts usage, 
BMI, diabetes and preoperative LVEF. Patients receiving the RA were two years younger and 
more likely to have insulin treated diabetes and decreased LVEF. After PS matching, the two 
groups were comparable for all pre-treatment characteristics (Table 2, Figure 1).  
Hospital outcomes 
Hospital outcomes are reported in Table 3. Mortality rates and postoperative complications 
were comparable between the two groups.  
5 year-outcomes 
Five-year outcomes are reported in Table 4. The rate of MACE was 8.8% (6.5-11.0) versus 
13.6% (10.8-16.3) in the RA and SVG groups respectively. The use of a RA graft was 
associated with significantly lower risk for MACE (HR 0.60; 95%CI 0.41-0.85; P= 0.005). 
This result was mainly determined by a significantly lower risk for repeat revascularization in 
the RA group (4.4%; 95%CI 2.8-6.0) when compared with the SVG group (7.6%; 95%CI 5.5- 
9.7) (HR 0.59; 95%CI 0.36-0.95; P=0.03) (Figure 2). When compared with the SVG group, 
the RA group had a non-significant lower risk of MI (HR 0.68; 95%CI 0.34-1.38; P=0.30), CV 
death (HR 0.83; 95%CI 0.46-1.51; P=0.55) and overall death (HR 0.83; 95%CI 0.54-1.27; P= 
0.39). The use of a RA graft remained associated with a lower incidence of MACE when the 
analysis also accounted for the clustering by individual surgeons (mixed effect HR 0.55; 
95%CI 0.35-0.87; P=0.01) and hospital (mixed effect HR 0.59; 95%CI 0.41-0.86; P=0.005). 
When the analysis was restricted to patients requiring grafts only to the left coronary system, 
there was a larger but not significantly lower risk for the RA group (HR 0.25; 95%CI 0.05-
1.17). We saw no associations with better outcomes using a RA graft without additional SVG 
(HR 0.71; 95%CI 0.46-1.10) when compared with the RA with additional SVG (HR 0.40; 
95%CI 0.20-0.78).    
Postoperative medications  
Medications prescribed at discharge are reported in Supplementary Table 2. Patients receiving 
a RA graft were more likely to be discharged on CCA, although only 29% of them received 
CCA. At 5-year follow-up, only 112 patients in the RA group were on CCA, of which 44 
patients were initially discharged on CCA. Patients in the SVG group were more likely to be 
discharged on dual-antiplatelet therapy with clopidogrel. After adjustment for medications 
prescribed at discharge, the use of the RA remained associated with lower 5-year MACE rates 
(adjusted HR 0.59; 95%CI 0.39-0.91; P=0.01).  Among patients receiving a RA graft, CCA 
prescribed at discharge was associated with a numerically lower incidence of MACE (5.2% vs 
10.2%; P=0.2; Figure 3).  
Modifiers of the Associations between RA Graft Use and Outcomes 
None of possible modifiers of association investigated was found to influence the associations 
between RA graft use and MACE when compared with SVG only (Figure 4). Subgroup 
analysis showed that the association between the RA and lower risk of MACE was present for 
both SITA and BITA grafts (interaction P=0.62; Supplementary Table 3, Supplementary 
Figure 3 and Supplementary Figure 4).  
Angiographic follow-up 
Angiographic follow-up was performed only in symptomatic patients and therefore patency 
rates of different conduits could not be analyzed. For those who underwent repeat 
revascularization, clinical presentation and revascularization strategy adopted were not 
available in all cases. In the RA group, graft failure and native coronary disease progression 
were documented in 4 and 21 cases respectively among 27 cases of repeat revascularization. 
In the SVG group, graft failure and native coronary disease progression were documented in 
54 and 90 cases respectively among 152 cases of repeat revascularization. All failed grafts were 
reported to be SVG. In the RA group, need for repeat CABG and repeat PCI was documented 
in 2 and 23 cases respectively. In the SVG group, need for repeat CABG and repeat PCI was 
documented in 6 and 113 cases respectively. 
 
Discussion 
The main finding of the present analysis is that a RA graft (with or without additional vein 
graft) used to supplement either SITA and BITA grafts instead of SVG only, was associated 
with ignificantly lower risk for major adverse cardiac events with a significantly lower rate of 
reintervention and marginally lower risk for CV death and subsequent MI, despite the fact that 
the quality of RA targets was not superior to SVG targets. On the other hand, use of a RA graft 
did not increase operative mortality or complications.  
Although several randomized trials have shown that use of a RA graft is associated with 
superior 5 year patency rates when compared with SVGs [3,4], whether this translates into 
better clinical outcomes remains uncertain. In fact, randomized controlled trials conducted to 
date are limited by small sample sizes and the results are inconclusive. The Radial Artery 
Versus Saphenous Vein Patency Randomized (RSVP) Trial [4] compared 82 and 60 patients 
randomized to receive the SITA and RA grafts or SITA and SVGs. The only robust clinical 
outcome assessed was mortality. The 5-year survival rate was 94.4%, with no significant 
difference in survival between the 2 groups. In the Radial Artery Patency and Clinical Outcome 
(RAPCO) Study [5], patients aged 70 years or more were randomly assigned to receive either 
SITA and RA grafts (n=73) or SITA and SVGs grafts (n=80). At 5-year follow-up, cardiac 
event-free survival estimates were 0.84 (95% CI 0.64-0.99) for the RA subgroup and 0.89 (95% 
CI 0.72-0.99) for the SVG subgroup. Petrovic, et al. [6] randomized 200 patients to receive 
either SITA and RA grafts or SITA and SVGs. They found no difference in 8 year clinical 
outcomes. In a larger trial by Goldman, et al. [21], 757 patients were randomly assigned to 
receive either SITA and RA grafts (n=366) or SITA and SVGs grafts (n=367). There was no 
significant difference between the 2 groups at 1 year in terms of death, myocardial infarction, 
stroke, and repeat coronary revascularization. However, outcomes beyond 1 year are not 
available.  
On the other hand, several retrospective studies that investigated the associations between the 
use of RA used as additional arterial conduit instead of SVG and outcomes reported discordant 
results for survival. Schwann, at al. [7] compared SITA+RA and SITA+SVG in two 
institutional US cohorts. Kaplan-Meier survival was significantly better for radial artery 
grafting (P < 0.001). Hayward, et al. [8] compared 1832 patients who received at least one RA 
graft in addition to SITA with 749 (29%) who received SITA and veins only from a multicenter 
database. At 7 years, survival rates between the RA and SVG groups were similar (RA: 75 ± 
2.6% vs SVG: 74 ± 2.9%, P = 0.65). A few studies have investigated the associations between 
using RA grafts and survival in the context of BITA grafting with conflicting results. Di Mauro 
and colleagues [12] reported survival at 8 years of 91.9% ± 2.9% among 87 patients undergoing 
BITA+RA grafting and 95.6% ± 0.9% among patients undergoing BITA+SVG (P = 0.12). 
More recently, Grau and coworkers [13] published a series of 183 patients undergoing 
BITA+RA grafting. Long-term survival in the BITA+RA groups were comparable to those in 
the BITA+SVG groups (P = .25). Mohammadi and associates [14] have reported comparable 
long-term survival in 249 matched pairs of patients undergoing BITA+RA versus BITA+SVG 
(P = 0.44). Shi, et al. [15] compared 262 matched patient-pairs of BITA+RA and BITA+SVG. 
BITA+RA and at 15 years, BITA + RA patients experienced better risk-adjusted survival (72 
± 6.0% vs 82 ± 5.2%, P = 0.02). Finally, we have reported a longer term survival comparison 
in 275 matched patient-pairs of BITA+RA and BITA+SVG from a single institution [16], and 
the two groups showed comparable 15 year survival rates (log-rank P = 0.54).  
The present post-hoc ART analyses support the hypothesis that an additional RA may reduce 
mid-term major adverse cardiac events when used to supplement either SITA or BITA grafts 
when compared with SVG only. The better clinical outcomes observed in patients receiving a 
RA graft can be attributed to its superior patency rate when compared with SVG [2,3,22]. 
Moreover, it has been shown that RA grafting has a strong protective effect against progression 
of native coronary artery disease in previously grafted vessels that can translate into reduced 
incidence of adverse cardiac events [23].  
An interim analysis of the ART [1] has shown that BITA grafts did not improve 5 year 
outcomes when compared with a SITA strategy. However, the primary endpoint of the ART is 
10-year survival and those data will be needed to draw any conclusions on whether there is any 
potential benefit of BITA grafts over the longer term. Previous studies have supported the 
hypothesis that the beneficial effect from BITA on clinical outcomes may be delayed by as 
much as 7 to 10 years [24].  On the other hand, the RA graft is simple to perform as its caliber 
and handling properties are similar to vein grafts. The superior patency rate of the RA over 
SVGs at 5 years has been demonstrated by several randomized controlled trials [2] and the use 
of a RA graft has been reported to exhibit maximal benefit between 0.5 and 5 years [7]. 
Main limitations of the present analyses are the nonrandomized comparison and the low 
number of outcome events. Propensity score modeling included several variables, but we 
cannot exclude a residual selection bias based on a unmeasured or unmeasurable 
characteristics.  
In conclusion, the present post-hoc analysis of the ART showed that the use of an additional 
RA graft to supplement both SITA and BITA grafts was associated with a lower risk for MACE 
at 5 years. Based on these results, it seems reasonable to consider the use of a RA graft a valid 
option for multiple arterial grafting. 
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Figure Legend 
Figure 1. Changes in standardized mean difference (SMD) between the radial artery (RA) and 
the saphenous vein graft (SVG) groups before and after propensity score matching (SMD: 
standardized mean difference; BMI: Body mass index; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; NYHA: New York Heart Association; UA: unstable angina; COPD: 
Chronic obstructive pulmonary disease; PVD: peripheral vascular disease; TIA: transint 
ischemic attack; CVA: cerebrovascular accident; MI: myocardial infarction; PCI: percutaneous 
coronary intervention; AF: atrial fibrillation; LVEF: left ventricular ejection fraction; DAPT: 
dual antiplatelet therapy; BITA bilateral internal thoracic artery; LMSD: left main stem 
disease; LAD: left anterior descending artery disease; CX: circumflex disease; DIA: diagonal 
branch disease; RCA: right coronary artery disease).  
Figure 2. Cumulative incidence of myocardial infarction (MI), revascularization, 
cardiovascular (CV) death and the composite of major adverse cardiac event (MACE) in the 
Radial artery (RA) and Saphenous Vein Graft (SVG) group respectively after matching.  
Figure 3. Cumulative incidence of the composite of major adverse cardiac event (MACE) in 
the Radial artery (RA) according to calcium channel antagonists (CCA) prescribed at 
discharge.  
Figure 4. Subgroup analysis and interaction analysis on the effect of the radial artery (RA) over 
saphenous vein graft (SVG) on the composite of major adverse cardiac event (MACE) 
  
Table 1. Conduits and relative targets details in the RA (top) and SVG (bottom) groups  
* for LITA and RITA, numbers refer to non in-situ configuration 
LITA: left internal thoracic artery; RA: radial artery; RITA: right internal thoracic artery; SVG: 
saphenous vein graft; CX: circumflex; LAD: left anterior descending artery; DIA; diagonal 
branch; RCA: right coronary artery   
 RA group (n=632) 
 LITA other RA RITA SVG 
N conduits used 627 4 362 278 235 
N of distal anastomosis  700 4 789 291 316 
Sequential anastomosis  131 (18.7) 2 (50.0) 163 (20.7) 27 (9.3) 21 (6.6) 
Proximal Anastomosis* n(%)       
 Aorta  34 (16.3) 1 (25.0) 574 (73.4) 20 (16.8) 304 (97.1) 
 Other conduit 175 (83.7) 3 (75.0) 208 (26.6) 99 (83.2) 9 (2.9) 
 Target n (%)      
        CX  130 (18.6) 2 (50.0) 394 (49.9) 123 (42.3) 75 (23.7) 
        DIA  75 (10.7) 0 (0.0) 75 (9.5) 21 (7.2) 57 (18.0) 
        LAD 493 (70.4) 0 (0.0) 24 (3.0) 133 (45.7) 2 (0.6) 
        RCA 2 (0.3) 2 (50.0) 296 (37.5) 14 (4.8) 182 (57.6) 
Vessel_diameter (mean (sd)) 1.79 (0.35) 1.75 (0.20) 1.73 (0.38) 1.79 (0.37) 1.70 (0.33) 
Vessel quality n (%)      
        Good  287 (41.5) 2 (50.0) 296 (37.9) 102 (35.5) 141 (45.8) 
        Satisfactory 327 (47.3) 1 (25.0) 419 (53.6) 144 (50.2) 135 (43.8) 
        Poor 78 (11.3) 1 (25.0) 66 (8.5) 41 (14.3) 32 (10.4) 
Endarterectomy n (%) 1 ( 0.1) 0 (0.0) 10 (1.3) 4 (1.4) 2 (0.6) 
      
      
 SVG group (n=2105) 
 LITA other RA RITA SVG 
N conduits used 2079 0 0 801 2015 
N of distal anastomosis  2221 0 0 825 3877 
Sequential anastomosis 182 (8.2) - - 43 (5.2) 271 (7.0) 
Proximal Anastomosis* n(%)  - -   
Aorta  48 (16.7) - - 66 (22.2) 3713 (96.2) 
Other conduit 237 (82.3) - - 229 (77.1) 145 ( 3.8) 
Target n (%)      
        CX  356 (16.0)   377 (45.7) 1673 (43.2) 
        DIA  176 (7.9) - - 53 (6.4) 480 (12.4) 
        LAD 1687 (76.0) - - 378 (45.8) 71 (1.8) 
        RCA 2 (0.1) - - 17 (2.1) 1653 (42.6) 
Vessel_diameter (mean (sd)) 1.86 (0.46) - - 1.87 (0.44) 1.83 (0.51) 
Vessel quality      
       Good 1048 (48.1) - - 397 (49.2) 1816 (47.7) 
       Satisfactory 813 (37.3) - - 295 (36.6) 1555 (40.9) 
       Poor 317 (14.6) - - 115 (14.3) 433 (11.4) 
Endarterectomy (%) 10 (0.5) - - 3 ( 0.4) 32 ( 0.8) 
Table 2. Baseline characteristics in the RA and unmatched and matched SVG group respectively with relative P value and standardized mean 
difference.   
 RA group SVG group 
(unmatched) 
P SMD SVG group 
(matched) 
P SMD 
N 632 2105   632   
Age (mean (sd)) 62.30 (9.08) 64.01 (8.88) <0.001 0.190 62.64 (8.96) 0.51 0.037 
Female, n(%) 80 (12.7) 288 (13.7) 0.55 0.030 80 (12.7) 1.000 <0.001 
BMI (mean (sd)) 28.63 (4.01) 28.13 (3.97) 0.006 0.124 28.85 (4.24) 0.32 0.056 
SBP (mean (sd)) 132.49 (18.85) 131.56 (17.82) 0.26 0.050 132.14 (18.22) 0.74 0.019 
DBP (mean (sd)) 74.98 (11.37) 74.98 (10.91) 0.99 0.001 74.30 (10.95) 0.28 0.061 
Creatinine mmol/L (mean (sd)) 96.00 (20.97) 97.23 (21.87) 0.21 0.057 96.43 (21.20) 0.72 0.020 
NYHA III/IV , n(%) 106 (16.8) 478 (22.7) 0.002 0.150 102 (16.1) 0.82 0.017 
Unstable Angina , n(%) 41 ( 6.5) 166 ( 7.9) 0.28 0.054 48 ( 7.6) 0.51 0.043 
Treated Hypertension , n(%) 471 (74.5) 1653 (78.5) 0.04 0.095 471 (74.5) 1.00 <0.001 
Treated Hyperlipidemia , n(%) 588 (93.0) 1981 (94.1) 0.37 0.044 590 (93.4) 0.91 0.013 
Diabetes,  n(%)   0.07 0.099  0.97 0.014 
   No history of diabetes 465 (73.6) 1614 (76.7)   461 (72.9)   
   Insulin treated diabetes  46 ( 7.3) 106 ( 5.0)   47 ( 7.4)   
   Non insulin treated diabetes  121 (19.1) 385 (18.3)   124 (19.6)   
Smoking, n(%)   0.47 0.056  0.91 0.025 
    Current smoking   94 (14.9) 290 (13.8)   89 (14.1)   
    Ex-smoker  345 (54.6) 1207 (57.3)   351 (55.5)   
    Never smoked  193 (30.5) 608 (28.9)   192 (30.4)   
COPD , n(%) 11 ( 1.7) 60 ( 2.9) 0.16 0.074 12 ( 1.9) 1.00 0.012 
Asthma, n(%) 30 ( 4.7) 88 ( 4.2) 0.61 0.027 28 ( 4.4) 0.89 0.015 
PVD, n(%) 45 ( 7.1) 148 ( 7.0) 1.00 0.003 51 ( 8.1) 0.60 0.036 
TIA, n(%) 19 ( 3.0) 85 ( 4.0) 0.28 0.056 13 ( 2.1) 0.37 0.060 
CVA, n(%) 15 ( 2.4) 67 ( 3.2) 0.36 0.049 12 ( 1.9) 0.70 0.033 
MI, n(%) 260 (41.1) 891 (42.3) 0.63 0.024 269 (42.6) 0.65 0.029 
PCI, n(%) 86 (13.6) 332 (15.8) 0.21 0.061 91 (14.4) 0.75 0.023 
AF pre, n(%) 8 ( 1.3) 32 ( 1.5) 0.78 0.022 11 ( 1.7) 0.64 0.039 
LVEF pre, n(%)   0.09 0.100  0.88 0.028 
     ≥50% 454 (71.8) 1602 (76.1)   446 (70.6)   
    31-49% 163 (25.8) 456 (21.7)   170 (26.9)   
    ≤30%  15 ( 2.4) 47 ( 2.2)   16 ( 2.5)   
DAPT pre, n(%) 135 (21.4) 484 (23.0) 0.42 0.039 152 (24.1) 0.28 0.064 
Antiplatelet within 3 days , n(%) 96 (15.2) 350 (16.6) 0.43 0.039 91 (14.4) 0.75 0.022 
Nitrates pre , n(%) 249 (39.4) 1079 (51.3) <0.001 0.240 255 (40.3) 0.77 0.019 
OFF-PUMP , n(%)   239 (37.8) 842 (40.0) 0.35 0.045 247 (39.1) 0.69 0.026 
BITA , n(%) 273 (43.2) 775 (36.8) 0.004 0.130 272 (43.0) 1.00 0.003 
LMSD, n(%) 142 (22.5) 410 (19.5) 0.11 0.074 134 (21.2) 0.63 0.031 
LAD, n(%) 625 (98.9) 2073 (98.5) 0.56 0.036 625 (98.9) 1.00 <0.001 
CX , n(%) 581 (91.9) 1952 (92.7) 0.56 0.030 576 (91.1) 0.69 0.028 
DIA, n(%) 221 (35.0) 691 (32.8) 0.34 0.045 228 (36.1) 0.72 0.023 
RCA , n(%) 469 (74.2) 1598 (75.9) 0.41 0.039 473 (74.8) 0.85 0.015 
N grafts (%)   0.84 0.053  0.82 0.070 
  2  69 (10.9) 246 (11.7)   78 (12.3)   
  3  332 (52.5) 1119 (53.2)   314 (49.7)   
  4  191 (30.2) 630 (29.9)   201 (31.8)   
  5  38 ( 6.0) 104 ( 4.9)   36 ( 5.7)   
  6  2 ( 0.3) 6 ( 0.3)   3 ( 0.5)   
RA: radial artery; SVG: saphenous vein graft; SMD: standardized mean difference; BMI: Body mass index; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; NYHA: New York Heart Association; UA: unstable angina; COPD: Chronic obstructive pulmonary disease; PVD: 
peripheral vascular disease; TIA: transint ischemic attack; CVA: cerebrovascular accident; MI: myocardial infarction; PCI: percutaneous 
coronary intervention; AF: atrial fibrillation; LVEF: left ventricular ejection fraction; DAPT: dual antiplatelet therapy; BITA bilateral internal 
thoracic artery; LMSD: left main stem disease; LAD: left anterior descending artery; CX: circumflex; DIA: diagonal; RCA: right coronary 
artery.  
  
Table 3. Hospital outcomes  
 RA group SVG group 
(unmatched) 
P* SVG group 
(matched) 
Pǂ 
N 632 2105  632  
Death, n(%)  9 (1.4) 20 (1.0) 0.42 5 (0.8) 0.42 
Return to operating room, n(%)  27 (4.3) 72 (3.4) 0.38 19 (3.0) 0.29 
IABP post, n(%)  21 (3.3) 91 (4.3) 0.32 29 (4.6) 0.31 
Renal replacement therapy, n(%)  45 (7.1) 100 (4.8) 0.03 36 (5.7) 0.36 
Sternal wound infection, n(%)  25 (4.0) 67 (3.2) 0.41 19 (3.0) 0.44 
MI, n(%)  6 (0.9) 40 (1.9) 0.15 15 (2.4) 0.08 
CVA, n(%)  5 (0.8) 31 (1.5) 0.26 5 (0.8) 1.00 
Repeat Revascularization, n(%)  2 (0.3) 13 (0.6) 0.55 5 (0.8) 0.45 
POAF, n(%)  152 (24.1) 524 (24.9) 0.71 165 (26.1) 0.44 
*chi squared test (binary outcomes) and paired t-test (continuous outcomes) 
ǂ McNemar's test (binary outcomes) and paired t-test (continuous outcomes) 
RA: Radial artery; SVG: saphenous vein graft; IABP: intra-aortic balloon pump; MI: myocardial infarction; CVA: cerebral vascular accident; 
POAF: postoperative atrial fibrillation.  
  
Table 4. Five-year outcomes rates (95% confidence interval, CI) 
 RA group SVG group 
(unmatched) 
P* SVG group 
(matched) 
Pǂ 
n 632 2105  632  
MI 14 (2.3%[1.1-3.4]) 78(3.7%[2.9-4.6]) 0.07 21(3.4%[2.0-4.8]) 0.30 
Repeat revascularization 27(4.4%[2.8-6.0]) 152(7.3%[6.2-8.5]) 0.008 47(7.6%[5.5- 9.7) 0.033 
CV death 22(3.5%[2.1-5.0]) 73(3.5%[2.7-4.3]) 0.99 25(4.0%[2.5-5.6]) 0.55 
Overall death 45 (7.3%(5.2-9.3]) 189(9.2%[7.9-10.4]) 0.15 51(8.3%[6.1-10.5]) 0.39 
CV death/MI/repeat revascularization 53(8.8%[6.5--11.0]) 261 (12.9%[11.4-14.3]) 0.005 82(13.6%[10.8-16.3]) 0.005 
* unadjusted Cox model 
ǂ Cox model stratified for matched pairs   
RA: radial artery; SVG: saphenous vein graft; CV: cardiovascular; MI: myocardial infarction 
 
 
